Titlebook: Clinical Trials in Latin America: Where Ethics and Business Clash; Nuria Homedes,Antonio Ugalde Book 2014 Springer International Publishin

鈍劍

Conference proceedings 2022Latest editionome countries will have to fight for a more ethical way of conducting clinical trials. In our opinion, the trials will need to be implemented by institutions that do not have monetary incentives. It may take some time before the change occurs, but it will happen.

圓柱

Clinical Trials in Latin America: Where Ethics and Business Clash978-3-319-01363-3Series ISSN 2212-9529 Series E-ISSN 2212-9537

配置

Nigel Hoschke,Don C. Price,D. Andrew Scotthics (Red Latino Americana de ética y Medicamentos –RELEM) and to the preparation of this manuscript. As the pharmaceutical markets and pharmaceutical research is increasingly globalized, the need to create global networks to promote access and the appropriate use of pharmaceuticals and the rights o

比目魚

Nigel Hoschke,Don C. Price,D. Andrew Scottnalyzes the different ethical codes that have been accepted by governments and professional associations in Latin American countries. After describing how the different international ethical research codes were drafted, have been changed and are being applied, the authors characterize the reasons wh

exhibit

organism

Cupidity

Nicholas J. Macias,Lisa J. K. Durbecks total population. This chapter describes the evolution of the provincial regulatory framework, the organizational environment that allowed the development of a private research center within the premises of a public hospital, and the ensuing collusion between researchers and clinicians..Changes of

過于平凡

Self-Organizing Digital Systemsmerican investigators. The country’s return to democracy and the documentation of ethical abuses while conducting clinical trials triggered the need to develop norms and regulations..The chapter describes the process followed by the National Health Council, an entity created to increase social contr

馬具

高談闊論

Tino Schlegel,Ryszard Kowalczykll country concentrates a disproportionate number of clinical trials, especially with pediatric populations, which are conducted by a handful of physicians. The regulation of clinical trials is incomplete and its analysis reflects the tensions among four different interest groups: (1) The Ministry o